{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:24:10Z","timestamp":1793665450534,"version":"4.5.1"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Interferon gamma (IFN\u03b3) is a critical cytokine known for its diverse roles in immune regulation, inflammation, and tumor surveillance. However, while IFN\u03b3\u00a0levels were elevated in sera of most newly diagnosed acute myeloid leukemia (AML) patients, its complex interplay in AML remains insufficiently understood. We aim to characterize these complex interactions through comprehensive bulk and single-cell approaches in bone marrow of newly diagnosed AML patients. We identify monocytic AML as having a unique microenvironment characterized by IFN\u03b3 producing T and NK cells, high IFN\u03b3 signaling, and immunosuppressive features. IFN\u03b3 signaling score\u00a0strongly correlates with venetoclax resistance\u00a0in\u00a0primary AML patient cells.\u00a0Additionally,\u00a0IFN\u03b3 treatment of primary AML patient cells increased\u00a0venetoclax resistance.\u00a0Lastly, a parsimonious 47-gene IFN\u03b3 score demonstrates robust prognostic value. In summary, our findings suggest that inhibiting\u00a0IFN\u03b3 is\u00a0a potential treatment strategy to overcoming venetoclax resistance and immune evasion in AML patients.<\/jats:p>","DOI":"10.1038\/s41467-024-45916-6","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T12:02:15Z","timestamp":1709121735000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Comprehensive characterization of IFN\u03b3 signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies"],"prefix":"10.1038","volume":"15","author":[{"given":"Bofei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8433-3360","authenticated-orcid":false,"given":"Patrick K.","family":"Reville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7196-9503","authenticated-orcid":false,"given":"Mhd Yousuf","family":"Yassouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3791-3204","authenticated-orcid":false,"given":"Fatima Z.","family":"Jelloul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8620-3735","authenticated-orcid":false,"given":"Christopher","family":"Ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poonam N.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamella","family":"Borges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Veletic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0285-6266","authenticated-orcid":false,"given":"Enes","family":"Dasdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6173-9074","authenticated-orcid":false,"given":"Jared K.","family":"Burks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9482-4806","authenticated-orcid":false,"given":"Guilin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengnan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Araceli Isabella","family":"Garza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2229-9756","authenticated-orcid":false,"given":"Cedric","family":"Nasnas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole R.","family":"Vaughn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0618-4798","authenticated-orcid":false,"given":"Natalia","family":"Baran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jairo","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preethi H.","family":"Gunaratne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinler A.","family":"Antunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4079-6632","authenticated-orcid":false,"given":"Suhendan","family":"Ekmekcioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9140-0610","authenticated-orcid":false,"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam B.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branko","family":"Cuglievan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9043-371X","authenticated-orcid":false,"given":"Dapeng","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval","family":"Daver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6309-9472","authenticated-orcid":false,"given":"Michael R.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-2212","authenticated-orcid":false,"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8663-2671","authenticated-orcid":false,"given":"Andrew","family":"Futreal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean M.","family":"Post","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2946-3562","authenticated-orcid":false,"given":"Hussein A.","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,28]]},"reference":[{"key":"45916_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner, H., Weisdorf, D. J. & Bloomfield, C. D. Acute myeloid leukemia. N. Engl. J. Med. 373, 1136\u20131152 (2015).","journal-title":"N. Engl. J. Med."},{"key":"45916_CR2","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil, E. et al. Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J. Med. 374, 2209\u20132221 (2016).","journal-title":"N. Engl. J. Med."},{"key":"45916_CR3","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"JW Tyner","year":"2018","unstructured":"Tyner, J. W. et al. Functional genomic landscape of acute myeloid leukaemia. Nature 562, 526\u2013531 (2018).","journal-title":"Nature"},{"key":"45916_CR4","doi-asserted-by":"publisher","unstructured":"TCGA. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059-2074 (2013). https:\/\/doi.org\/10.1056\/NEJMoa1301689.","DOI":"10.1056\/NEJMoa1301689"},{"key":"45916_CR5","doi-asserted-by":"publisher","first-page":"e922","DOI":"10.1016\/S2352-3026(21)00270-2","volume":"8","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian, H. et al. Harnessing the benefits of available targeted therapies in acute myeloid leukaemia. Lancet Haematol. 8, e922\u2013e933 (2021).","journal-title":"Lancet Haematol."},{"key":"45916_CR6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo, C. D. et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N. Engl. J. Med. 383, 617\u2013629 (2020).","journal-title":"N. Engl. J. Med"},{"key":"45916_CR7","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1182\/blood.2022016963","volume":"140","author":"AH Wei","year":"2022","unstructured":"Wei, A. H. et al. Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy. Blood 140, 2754\u20132756 (2022).","journal-title":"Blood"},{"key":"45916_CR8","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1200\/JCO.20.03736","volume":"39","author":"CD DiNardo","year":"2021","unstructured":"DiNardo, C. D. et al. Venetoclax combined With FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia. J. Clin. Oncol. 39, 2768\u20132778 (2021).","journal-title":"J. Clin. Oncol."},{"key":"45916_CR9","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1016\/S2352-3026(21)00192-7","volume":"8","author":"TM Kadia","year":"2021","unstructured":"Kadia, T. M. et al. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol. 8, e552\u2013e561 (2021).","journal-title":"Lancet Haematol."},{"key":"45916_CR10","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","volume":"10","author":"S Pei","year":"2020","unstructured":"Pei, S. et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 10, 536\u2013551 (2020).","journal-title":"Cancer Discov."},{"key":"45916_CR11","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1158\/2159-8290.CD-22-1297","volume":"13","author":"S Pei","year":"2023","unstructured":"Pei, S. et al. A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy. Cancer Discov. 13, 2032\u20132049 (2023).","journal-title":"Cancer Discov."},{"key":"45916_CR12","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/nature08851","volume":"464","author":"MH Raaijmakers","year":"2010","unstructured":"Raaijmakers, M. H. et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 464, 852\u2013857 (2010).","journal-title":"Nature"},{"key":"45916_CR13","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.stem.2016.08.021","volume":"19","author":"NA Zambetti","year":"2016","unstructured":"Zambetti, N. A. et al. Mesenchymal inflammation drives genotoxic stress in hematopoietic stem cells and predicts disease evolution in human pre-leukemia. Cell Stem Cell 19, 613\u2013627 (2016).","journal-title":"Cell Stem Cell"},{"key":"45916_CR14","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1158\/2159-8290.CD-21-0956","volume":"12","author":"JM Ellegast","year":"2022","unstructured":"Ellegast, J. M. et al. Unleashing cell-intrinsic inflammation as a strategy to kill AML blasts. Cancer Discov. 12, 1760\u20131781 (2022).","journal-title":"Cancer Discov."},{"key":"45916_CR15","doi-asserted-by":"publisher","first-page":"6392","DOI":"10.1182\/blood-2011-04-348144","volume":"118","author":"AG Fleischman","year":"2011","unstructured":"Fleischman, A. G. et al. TNF\u03b1 facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood 118, 6392\u20136398 (2011).","journal-title":"Blood"},{"key":"45916_CR16","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1182\/blood.V79.8.1938.1938","volume":"79","author":"Z Estrov","year":"1992","unstructured":"Estrov, Z. et al. Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors. Blood 79, 1938\u20131945 (1992).","journal-title":"Blood"},{"key":"45916_CR17","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1016\/j.celrep.2017.03.018","volume":"18","author":"A Carey","year":"2017","unstructured":"Carey, A. et al. Identification of interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia. Cell Rep. 18, 3204\u20133218 (2017).","journal-title":"Cell Rep."},{"key":"45916_CR18","doi-asserted-by":"publisher","first-page":"101299","DOI":"10.1016\/j.smim.2019.101299","volume":"43","author":"D Saleiro","year":"2019","unstructured":"Saleiro, D. & Platanias, L. C. Interferon signaling in cancer. Non-canonical pathways and control of intracellular immune checkpoints. Semin Immunol. 43, 101299 (2019).","journal-title":"Semin Immunol."},{"key":"45916_CR19","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nri1604","volume":"5","author":"LC Platanias","year":"2005","unstructured":"Platanias, L. C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5, 375\u2013386 (2005).","journal-title":"Nat. Rev. Immunol."},{"key":"45916_CR20","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1080\/10428194.2021.1948027","volume":"62","author":"H Jiang","year":"2021","unstructured":"Jiang, H. et al. Interferon-\u03b1 as maintenance therapy can significantly reduce relapse in patients with favorable-risk acute myeloid leukemia. Leuk. Lymphoma 62, 2949\u20132956 (2021).","journal-title":"Leuk. Lymphoma"},{"key":"45916_CR21","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/leu.2012.313","volume":"27","author":"M Talpaz","year":"2013","unstructured":"Talpaz, M., Hehlmann, R., Quint\u00e1s-Cardama, A., Mercer, J. & Cortes, J. Re-emergence of interferon-\u03b1 in the treatment of chronic myeloid leukemia. Leukemia 27, 803\u2013812 (2013).","journal-title":"Leukemia"},{"key":"45916_CR22","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","volume":"7","author":"H Gisslinger","year":"2020","unstructured":"Gisslinger, H. et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 7, e196\u2013e208 (2020).","journal-title":"Lancet Haematol."},{"key":"45916_CR23","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","volume":"379","author":"MJ Christopher","year":"2018","unstructured":"Christopher, M. J. et al. Immune escape of relapsed AML cells after allogeneic transplantation. N. Engl. J. Med. 379, 2330\u20132341 (2018).","journal-title":"N. Engl. J. Med."},{"key":"45916_CR24","first-page":"43","volume":"4","author":"J Qiu","year":"2023","unstructured":"Qiu, J. et al. Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction. Nat. Cancer 4, 43\u201361 (2023).","journal-title":"Nat. Cancer"},{"key":"45916_CR25","doi-asserted-by":"publisher","first-page":"eaaz0463","DOI":"10.1126\/scitranslmed.aaz0463","volume":"12","author":"J Vadakekolathu","year":"2020","unstructured":"Vadakekolathu, J. et al. Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia. Sci. Transl. Med. 12, eaaz0463 (2020).","journal-title":"Sci. Transl. Med."},{"key":"45916_CR26","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-16-0224","volume":"22","author":"M Mandai","year":"2016","unstructured":"Mandai, M. et al. Dual faces of IFN\u03b3 in cancer progression: a role of PD-L1 induction in the determination of pro- and antitumor immunity. Clin. Cancer Res 22, 2329\u20132334 (2016).","journal-title":"Clin. Cancer Res"},{"key":"45916_CR27","first-page":"4020","volume":"51","author":"SA Kelly","year":"1991","unstructured":"Kelly, S. A., Gschmeissner, S., East, N. & Balkwill, F. R. Enhancement of metastatic potential by gamma-interferon. Cancer Res. 51, 4020\u20134027 (1991).","journal-title":"Cancer Res."},{"key":"45916_CR28","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ccell.2022.12.008","volume":"41","author":"G Li","year":"2023","unstructured":"Li, G. et al. Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy. Cancer Cell 41, 304\u2013322.e307 (2023).","journal-title":"Cancer Cell"},{"key":"45916_CR29","doi-asserted-by":"publisher","first-page":"705627","DOI":"10.3389\/fonc.2021.705627","volume":"11","author":"HA Abbas","year":"2021","unstructured":"Abbas, H. A. et al. Decoupling lineage-associated genes in acute myeloid leukemia reveals inflammatory and metabolic signatures associated with outcomes. Front. Oncol. 11, 705627 (2021).","journal-title":"Front. Oncol."},{"key":"45916_CR30","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.3324\/haematol.11889","volume":"93","author":"P Alessandro","year":"2008","unstructured":"Alessandro, P. et al. M4 acute myeloid leukemia: the role of eosinophilia and cytogenetics in treatment response and survival. The GIMEMA experience. Haematologica 93, 1025\u20131032 (2008).","journal-title":"Haematologica"},{"key":"45916_CR31","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner, H. et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140, 1345\u20131377 (2022).","journal-title":"Blood"},{"key":"45916_CR32","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/s41591-022-01819-x","volume":"28","author":"AGX Zeng","year":"2022","unstructured":"Zeng, A. G. X. et al. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. Nat. Med. 28, 1212\u20131223 (2022).","journal-title":"Nat. Med."},{"key":"45916_CR33","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1126\/science.8016643","volume":"265","author":"V Steimle","year":"1994","unstructured":"Steimle, V., Siegrist, C. A., Mottet, A., Lisowska-Grospierre, B. & Mach, B. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 265, 106\u2013109 (1994).","journal-title":"Science"},{"key":"45916_CR34","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S0952-7915(99)80014-4","volume":"11","author":"K Fr\u00fch","year":"1999","unstructured":"Fr\u00fch, K. & Yang, Y. Antigen presentation by MHC class I and its regulation by interferon gamma. Curr. Opin. Immunol. 11, 76\u201381 (1999).","journal-title":"Curr. Opin. Immunol."},{"key":"45916_CR35","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman, A. M. et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol. 37, 773\u2013782 (2019).","journal-title":"Nat. Biotechnol."},{"key":"45916_CR36","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.4049\/jimmunol.157.4.1350","volume":"157","author":"LM Bradley","year":"1996","unstructured":"Bradley, L. M., Dalton, D. K. & Croft, M. A direct role for IFN-gamma in regulation of Th1 cell development. J. Immunol. 157, 1350\u20131358 (1996).","journal-title":"J. Immunol."},{"key":"45916_CR37","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.cell.2017.05.005","volume":"169","author":"AE Overacre-Delgoffe","year":"2017","unstructured":"Overacre-Delgoffe, A. E. et al. Interferon-\u03b3 drives treg fragility to promote anti-tumor immunity. Cell 169, 1130\u20131141.e1111 (2017).","journal-title":"Cell"},{"key":"45916_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26282-z","volume":"12","author":"HA Abbas","year":"2021","unstructured":"Abbas, H. A. et al. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nat. Commun. 12, 6071 (2021).","journal-title":"Nat. Commun."},{"key":"45916_CR39","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/nmeth.4463","volume":"14","author":"S Aibar","year":"2017","unstructured":"Aibar, S. et al. SCENIC: single-cell regulatory network inference and clustering. Nat. Methods 14, 1083\u20131086 (2017).","journal-title":"Nat. Methods"},{"key":"45916_CR40","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1158\/2643-3230.BCD-21-0050","volume":"3","author":"AA Petti","year":"2022","unstructured":"Petti, A. A. et al. Genetic and transcriptional contributions to relapse in normal karyotype acute myeloid leukemia. Blood Cancer Discov. 3, 32\u201349 (2022).","journal-title":"Blood Cancer Discov."},{"key":"45916_CR41","first-page":"27","volume":"4","author":"A Lasry","year":"2023","unstructured":"Lasry, A. et al. An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia. Nat. Cancer 4, 27\u201342 (2023).","journal-title":"Nat. Cancer"},{"key":"45916_CR42","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.immuni.2016.08.013","volume":"45","author":"D Sichien","year":"2016","unstructured":"Sichien, D. et al. IRF8 transcription factor controls survival and function of terminally differentiated conventional and plasmacytoid dendritic cells, respectively. Immunity 45, 626\u2013640 (2016).","journal-title":"Immunity"},{"key":"45916_CR43","doi-asserted-by":"publisher","unstructured":"M\u00f8ller, A.F. & Natarajan, K.N. Predicting gene regulatory networks from cell atlases. Life Sci Alliance 3 https:\/\/doi.org\/10.26508\/lsa.202000658 (2020).","DOI":"10.26508\/lsa.202000658"},{"key":"45916_CR44","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1097\/PAS.0000000000001765","volume":"45","author":"SG Katz","year":"2021","unstructured":"Katz, S. G., Edappallath, S. & Xu, M. L. IRF8 is a reliable monoblast marker for acute monocytic leukemias. Am. J. Surg. Pathol. 45, 1391\u20131398 (2021).","journal-title":"Am. J. Surg. Pathol."},{"key":"45916_CR45","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1158\/2643-3230.BCD-21-0207","volume":"3","author":"K Eagle","year":"2022","unstructured":"Eagle, K. et al. Transcriptional plasticity drives leukemia immune escape. Blood Cancer Discov. 3, 394\u2013409 (2022).","journal-title":"Blood Cancer Discov."},{"key":"45916_CR46","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","volume":"175","author":"P Andr\u00e9","year":"2018","unstructured":"Andr\u00e9, P. et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell 175, 1731\u20131743.e1713 (2018).","journal-title":"Cell"},{"key":"45916_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21246-9","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin, S. et al. Inference and analysis of cell-cell communication using CellChat. Nat. Commun. 12, 1088 (2021).","journal-title":"Nat. Commun."},{"key":"45916_CR48","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41592-019-0667-5","volume":"17","author":"R Browaeys","year":"2020","unstructured":"Browaeys, R., Saelens, W. & Saeys, Y. NicheNet: modeling intercellular communication by linking ligands to target genes. Nat. Methods 17, 159\u2013162 (2020).","journal-title":"Nat. Methods"},{"key":"45916_CR49","doi-asserted-by":"publisher","first-page":"67","DOI":"10.36401\/JIPO-21-X2","volume":"4","author":"F Haddad","year":"2021","unstructured":"Haddad, F. & Daver, N. Targeting CD47\/SIRP\u03b1 in acute myeloid leukemia and myelodysplastic syndrome: Preclinical and clinical developments of magrolimab. J. Immunother. Precis. Oncol. 4, 67\u201371 (2021).","journal-title":"J. Immunother. Precis. Oncol."},{"key":"45916_CR50","doi-asserted-by":"publisher","first-page":"102741","DOI":"10.1016\/j.jbc.2022.102741","volume":"299","author":"M G\u00f3mez-Herranz","year":"2023","unstructured":"G\u00f3mez-Herranz, M., Taylor, J. & Sloan, R. D. IFITM proteins: Understanding their diverse roles in viral infection, cancer, and immunity. J. Biol. Chem. 299, 102741 (2023).","journal-title":"J. Biol. Chem."},{"key":"45916_CR51","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41586-020-2884-6","volume":"588","author":"J Lee","year":"2020","unstructured":"Lee, J. et al. IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B cells. Nature 588, 491\u2013497 (2020).","journal-title":"Nature"},{"key":"45916_CR52","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak, A. et al. Defining a cancer dependency map. Cell 170, 564\u2013576.e516 (2017).","journal-title":"Cell"},{"key":"45916_CR53","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1080\/10428194.2022.2118533","volume":"63","author":"HA Abbas","year":"2022","unstructured":"Abbas, H. A. et al. Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment. Leuk. Lymphoma 63, 3105\u20133116 (2022).","journal-title":"Leuk. Lymphoma"},{"key":"45916_CR54","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-21-0410","volume":"12","author":"D Malani","year":"2022","unstructured":"Malani, D. et al. Implementing a functional precision medicine tumor board for acute myeloid leukemia. Cancer Discov. 12, 388\u2013401 (2022).","journal-title":"Cancer Discov."},{"key":"45916_CR55","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","volume":"58","author":"R Tibshirani","year":"1996","unstructured":"Tibshirani, R. Regression shrinkage and selection Via the Lasso. J. R. Stat. Soc.: Ser. B (Methodol.) 58, 267\u2013288 (1996).","journal-title":"J. R. Stat. Soc.: Ser. B (Methodol.)"},{"key":"45916_CR56","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41568-020-0245-2","volume":"20","author":"S M\u00e9ndez-Ferrer","year":"2020","unstructured":"M\u00e9ndez-Ferrer, S. et al. Bone marrow niches in haematological malignancies. Nat. Rev. Cancer 20, 285\u2013298 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"45916_CR57","doi-asserted-by":"publisher","first-page":"772408","DOI":"10.3389\/fimmu.2021.772408","volume":"12","author":"V Camacho","year":"2021","unstructured":"Camacho, V., Kuznetsova, V. & Welner, R. S. Inflammatory cytokines shape an altered immune response during myeloid malignancies. Front Immunol. 12, 772408 (2021).","journal-title":"Front Immunol."},{"key":"45916_CR58","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.it.2010.12.003","volume":"32","author":"MT Baldridge","year":"2011","unstructured":"Baldridge, M. T., King, K. Y. & Goodell, M. A. Inflammatory signals regulate hematopoietic stem cells. Trends Immunol. 32, 57\u201365 (2011).","journal-title":"Trends Immunol."},{"key":"45916_CR59","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","volume":"5","author":"M Kleppe","year":"2015","unstructured":"Kleppe, M. et al. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov. 5, 316\u2013331 (2015).","journal-title":"Cancer Discov."},{"key":"45916_CR60","doi-asserted-by":"publisher","unstructured":"Mojic, M., Takeda, K. & Hayakawa, Y. The Dark Side of IFN-\u03b3: Its role in promoting cancer immunoevasion. Int. J. Mol. Sci. 19 https:\/\/doi.org\/10.3390\/ijms19010089 (2017).","DOI":"10.3390\/ijms19010089"},{"key":"45916_CR61","doi-asserted-by":"publisher","unstructured":"Song, E & Chow, R.D. Mutations in IFN-\u03b3 signaling genes sensitize tumors to immune checkpoint blockade. Cancer Cell https:\/\/doi.org\/10.1016\/j.ccell.2023.02.013.","DOI":"10.1016\/j.ccell.2023.02.013"},{"key":"45916_CR62","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/s41592-021-01274-5","volume":"18","author":"P Jiang","year":"2021","unstructured":"Jiang, P. et al. Systematic investigation of cytokine signaling activity at the tissue and single-cell levels. Nat. Methods 18, 1181\u20131191 (2021).","journal-title":"Nat. Methods"},{"key":"45916_CR63","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.22.00227","volume":"40","author":"RS Herbst","year":"2022","unstructured":"Herbst, R. S. et al. COAST: An open-label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage III non\u2013small-cell lung cancer. J. Clin. Oncol. 40, 3383\u20133393 (2022).","journal-title":"J. Clin. Oncol."},{"key":"45916_CR64","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ccell.2023.01.001","volume":"41","author":"X Liu","year":"2023","unstructured":"Liu, X. et al. Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance. Cancer Cell 41, 272\u2013287.e279 (2023).","journal-title":"Cancer Cell"},{"key":"45916_CR65","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3324\/haematol.2009.010595","volume":"95","author":"MM van Luijn","year":"2010","unstructured":"van Luijn, M. M. et al. Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses. Haematologica 95, 485\u2013493 (2010).","journal-title":"Haematologica"},{"key":"45916_CR66","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1158\/0008-5472.CAN-10-3689","volume":"71","author":"MM van Luijn","year":"2011","unstructured":"van Luijn, M. M. et al. Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells. Cancer Res. 71, 2507\u20132517 (2011).","journal-title":"Cancer Res"},{"key":"45916_CR67","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/bmt.2008.380","volume":"43","author":"S Nguyen","year":"2009","unstructured":"Nguyen, S. et al. HLA-E upregulation on IFN-gamma-activated AML blasts impairs CD94\/NKG2A-dependent NK cytolysis after haplo-mismatched hematopoietic SCT. Bone Marrow Transpl. 43, 693\u2013699 (2009).","journal-title":"Bone Marrow Transpl."},{"key":"45916_CR68","doi-asserted-by":"publisher","unstructured":"Ranti, D. et al. Elevated HLA-E and NKG2A as a consequence of chronic immune activation defines resistance to <em>M. bovis<\/em> BCG immunotherapy in Non-Muscle-Invasive Bladder Cancer. bioRxiv, 2022.2003.2006.483198 (2022). https:\/\/doi.org\/10.1101\/2022.03.06.483198.","DOI":"10.1101\/2022.03.06.483198"},{"key":"45916_CR69","doi-asserted-by":"publisher","unstructured":"Ramos, A. et al. Leukemia-intrinsic determinants of CAR-T response revealed by iterative <em>in vivo<\/em> genome-wide CRISPR screening. bioRxiv, 2022.2002.2015.480217 (2022). https:\/\/doi.org\/10.1101\/2022.02.15.480217.","DOI":"10.1101\/2022.02.15.480217"},{"key":"45916_CR70","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1002\/eji.1830220933","volume":"22","author":"G Valente","year":"1992","unstructured":"Valente, G. et al. Distribution of interferon-gamma receptor in human tissues. Eur. J. Immunol. 22, 2403\u20132412 (1992).","journal-title":"Eur. J. Immunol."},{"key":"45916_CR71","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1016\/j.celrep.2016.11.031","volume":"17","author":"KA Matatall","year":"2016","unstructured":"Matatall, K. A. et al. Chronic infection depletes hematopoietic stem cells through stress-induced terminal differentiation. Cell Rep. 17, 2584\u20132595 (2016).","journal-title":"Cell Rep."},{"key":"45916_CR72","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41417-019-0093-y","volume":"27","author":"Y Liu","year":"2020","unstructured":"Liu, Y. et al. High IFITM3 expression predicts adverse prognosis in acute myeloid leukemia. Cancer Gene Ther. 27, 38\u201344 (2020).","journal-title":"Cancer Gene Ther."},{"key":"45916_CR73","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/bioinformatics\/bts034","volume":"28","author":"JT Leek","year":"2012","unstructured":"Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E. & Storey, J. D. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28, 882\u2013883 (2012).","journal-title":"Bioinformatics"},{"key":"45916_CR74","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-Seq data. BMC Bioinforma. 14, 7 (2013).","journal-title":"BMC Bioinforma."},{"key":"45916_CR75","doi-asserted-by":"publisher","unstructured":"Desai, P. N. et al. Single-Cell Profiling of CD8+ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion. Cancer Immunol. Res. CIR-22-0961. https:\/\/doi.org\/10.1158\/2326-6066.CIR-22-0961 (2023).","DOI":"10.1158\/2326-6066.CIR-22-0961"},{"key":"45916_CR76","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.cell.2017.05.035","volume":"169","author":"C Zheng","year":"2017","unstructured":"Zheng, C. et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell 169, 1342\u20131356.e1316 (2017).","journal-title":"Cell"},{"key":"45916_CR77","doi-asserted-by":"publisher","unstructured":"Rutella, S. et al. Immune dysfunction signatures predict outcomes and define checkpoint blockade\u2013unresponsive microenvironments in acute myeloid leukemia. J. Clin. Investig. 132 https:\/\/doi.org\/10.1172\/JCI159579 (2022).","DOI":"10.1172\/JCI159579"},{"key":"45916_CR78","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587.e3529 (2021).","journal-title":"Cell"},{"key":"45916_CR79","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.cels.2019.03.003","volume":"8","author":"CS McGinnis","year":"2019","unstructured":"McGinnis, C. S., Murrow, L. M. & Gartner, Z. J. DoubletFinder: Doublet detection in single-cell RNA sequencing data using artificial nearest neighbors. Cell Syst. 8, 329\u2013337.e324 (2019).","journal-title":"Cell Syst."},{"key":"45916_CR80","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289\u20131296 (2019).","journal-title":"Nat. Methods"},{"key":"45916_CR81","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1126\/science.1254257","volume":"344","author":"AP Patel","year":"2014","unstructured":"Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396\u20131401 (2014).","journal-title":"Science"},{"key":"45916_CR82","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","volume":"32","author":"Z Gu","year":"2016","unstructured":"Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847\u20132849 (2016).","journal-title":"Bioinformatics"},{"key":"45916_CR83","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47\u2013e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"45916_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v033.i01","volume":"33","author":"J Friedman","year":"2010","unstructured":"Friedman, J., Hastie, T. & Tibshirani, R. Regularization paths for generalized linear models via coordinate descent. J. Stat. Softw. 33, 1\u201322 (2010).","journal-title":"J. Stat. Softw."},{"key":"45916_CR85","doi-asserted-by":"publisher","unstructured":"Wang, B. et al. Comprehensive characterization of IFN\u03b3 signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies. 2023_IFNG_Inflammation. https:\/\/doi.org\/10.5281\/zenodo.10552903 2024.","DOI":"10.5281\/zenodo.10552903"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45916-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45916-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45916-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T04:02:30Z","timestamp":1731470550000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45916-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,28]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["45916"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-45916-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,28]]},"assertion":[{"value":"7 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.R.G reports research funding from Sanofi, Kite\/Gilead, Abbvie and Allogene; consulting for Abbvie, Allogene and Bristol Myers Squibb; honoraria from BMS, Daiichi Sankyo and DAVA Oncology; and stock ownership of KDAc Therapeutics. I.V. received research funding from Avilect Biosciences\/Aviceda Therapeutics.\u00a0H.A.A. reports research funding from Genentech and Enzyme-By-Design, consultancy fees from Molecular Partners, and inkind support from Illumina.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1821"}}